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Thisspecialissueontheoveractivebladderdealswithspeciﬁc
aspects of OAB with respect to pathophysiology, speciﬁc
patient populations, and treatments. The editorial board
selected 8 papers that address these special angles of the OAB
spectrum.
In the basic research section, Y. Kubota et al. describe the
role of KIT-positive cells in the urinary bladder. KIT staining
is used as a marker for interstitial cells. Latest publications
suggest that KIT is not only a detection marker of these cells
but also may play a crucial role in the control of bladder
function.
T. Antunes-Lopes et al. relate about the latest develop-
ments of biomarkers like nerve growth factor (NGF) and
brain derived neurotrophic factor (BDNF) and how useful
they are at this moment to be as biomarkers. It seems that
BDNF is the best future candidate for this goal.
With respect to medical treatment, three papers are
presented. The ﬁrst is from A. Athanasopoulos and K. Gian-
nitsas. In an overview about antimuscarinics, they conclude
that the diﬀerences are small and that individuals respond
diﬀerently to the various available drugs. A. Matsumori et al.
illustrate that it is possible to prescribe other antimuscarinics
when the ﬁrst one fails. They present data about the eﬀect
of propiverine in patients who failed other antimuscarinic
treatments for OAB. A special group of patients who
are treated with OAB is presented by F. van Rey and J.
Heesakkers. In a group of MS patients with OAB, the highly
beneﬁcial eﬀect of solifenacin is presented based on bladder
diaries and patient-reported outcome measures.
Another well-established treatment for OAB is pelvic
electrical neuromodulation presented by T. F. Al-Shaiji et al.
They review the indications, possible mechanisms of action,
surgical aspects and possible complications, and safety issues
of this technique.
Ac o m p l e t e l yd i ﬀerent type of neurostimulation for OAB
is described by F. M. J. Martens et al. They relate about the
results of the Finetech-Brindley neurostimulator in patients
with a complete spinal cord injury. This diﬃcult and time-
consuming surgery has various beneﬁcial eﬀects on as well
the urinary and the gastrointestinal tract. Moreover, the
sexual functions and the lower limb spasms may change to
the good with this exciting technique.
The last contribution in this special issue on OAB is from
J. Neuhaus et al. They present about a fairly diﬃcult and
special kid on the block: those suﬀering from bladder pain
syndrome or interstitial cystitis. They propose a new diag-
nostic model that includes extended diagnostics with molec-
ular markers. Diﬀerential diagnosis and tailored therapy
according to them should be based on three diagnostical
columns: clinical diagnostics, histopathology, and molecular
diagnostics. The future will tell whether this is way to go in
this diﬃcult-to-treat disturbance of the lower urinary tract.
The editorial board of this special issue hopes that these
topics give you more insight in the OAB spectrum and that
it gives new ideas to implement in basic research as well as
clinical practice.
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